Rankings
▼
Calendar
AMRX FY 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
FY 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$2.4B
+8.2% YoY
Gross Profit
$864M
36.1% margin
Operating Income
$204M
8.5% margin
Net Income
-$84M
-3.5% margin
EPS (Diluted)
$-0.48
Cash Flow
Operating Cash Flow
$346M
Free Cash Flow
$276M
Stock-Based Comp.
$27M
Balance Sheet
Total Assets
$3.5B
Total Liabilities
$3.4B
Stockholders' Equity
$20M
Cash & Equivalents
$92M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.4B
$2.2B
+8.2%
Gross Profit
$864M
$791M
+9.1%
Operating Income
$204M
-$95M
+315.3%
Net Income
-$84M
-$130M
+35.4%
← Q4 2022
All Quarters
Q1 2023 →